Company news
Molecular Partners Ag (SIX:MOLN) news
Molecular Partners Ag news releases on 6ix. Latest, Aug 25, 2026: Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3…
Press releases & updates
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
August 25, 2026
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
July 16, 2026
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
July 15, 2026
Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
July 6, 2026
Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
July 2, 2026
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
May 30, 2026
Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
May 26, 2026
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
May 12, 2026
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
May 4, 2026
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
May 1, 2026
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
April 19, 2026
Molecular Partners : statement regarding Passive Foreign Investment Company status
April 16, 2026
Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting
April 14, 2026
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors
March 23, 2026
Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes
March 19, 2026
Molecular Partners to Hold Three Poster Presentations at AACR 2026
March 17, 2026
Molecular Partners Reports Highlights and Financial Results for Full Year 2025
March 12, 2026
Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics
February 26, 2026
Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results
February 26, 2026
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
February 2, 2026
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
January 11, 2026
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics
December 11, 2025
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
December 7, 2025
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action
November 12, 2025
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting
November 3, 2025
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025
November 3, 2025
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025
October 30, 2025
Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025
August 25, 2025
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics
August 21, 2025
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025
June 22, 2025
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025
June 11, 2025
Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway
June 10, 2025
Molecular Partners to Present at Upcoming Investor Conferences
May 19, 2025
Molecular Partners Reports Financial Results and Highlights from Q1 2025
May 15, 2025
Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025
April 25, 2025
Molecular Partners Announces all Board Proposals Approved at Annual General Meeting
April 16, 2025
Molecular Partners to hold three poster presentations at AACR 2025
March 25, 2025
Molecular Partners Publishes Invitation to Annual General Meeting 2025
March 25, 2025
Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024
March 6, 2025
Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call
February 28, 2025